Get the Stockscreener App
1.29
0.00%
0.00
Icecure Medical Ltd Stock (ICCM) Latest News
Revolutionary Breast Cancer Treatment Shows 94% Success: Medical Experts Validate New Alternative to Surgery - StockTitan
IceCure Medical (NASDAQ:ICCM) Shares Down 1.6%Here's What Happened - MarketBeat
ICCMIceCure Medical Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod - MSN
IceCure submits application to China’s NMPA for cryoablation system approval - Yahoo! Voices
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China - The Malaysian Reserve
IceCure Medical (NASDAQ:ICCM) Stock Price Down 1.6% – Should You Sell? - Defense World
IceCure Medical Ltd. Files for Regulatory Approval of ProSense Cryoablation System in China - Marketscreener.com
Icecure Medical Announces Equity Distribution Agreement - TipRanks
IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025 - TipRanks
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America - Longview News-Journal
Investors bid IceCure Medical (NASDAQ:ICCM) up US$14m despite increasing losses YoY, taking five-year CAGR to 43% - Simply Wall St
The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing - Yahoo Finance
Financial Analysis: SANUWAVE Health (OTCMKTS:SNWV) versus IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - Kilgore News Herald
IceCure Medical regains full Nasdaq compliance - Medical Buyer
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minim - GuruFocus.com
IceCure to Meet Institutional Investors at the H.C. Wainwright a - GuruFocus.com
IceCure earns European patent win for next-gen cryoablation tech - Mass Device
IceCure Medical Ltd. Receives an Intention to Grant Notice from the European Patent Office - Marketscreener.com
Icecure Nicks Up On European OK For Connector - MENAFN.COM
IceCure Nicks Up on European OK for Connector - Baystreet.ca
European Patent Office Issues Intention to Grant Notice to IceCu - GuruFocus.com
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - Marketscreener.com
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference - GuruFocus.com
IceCure Medical appoints new board director - Investing.com India
IceCure Medical appoints new board director By Investing.com - Investing.com Australia
Icecure Medical Appoints New Board Director with Financial Expertise - TipRanks
IceCure Medical Ltd Appoints Li Haixiang as Director - Marketscreener.com
IceCure Medical (NASDAQ:ICCM) Stock Price Down 0.4%Here's Why - MarketBeat
IceCure Medical (NASDAQ:ICCM) Shares Down 0.4% – What’s Next? - Defense World
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - Marketscreener.com
IceCure Medical's ProSense Shows Breakthrough 5-Year Breast Cancer Treatment Results in Major Clinical Trial - StockTitan
Study Published in the British Journal of Radiology Demonstrates - GuruFocus.com
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies - The Eastern Progress Online
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - The Eastern Progress Online
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - Kilgore News Herald
IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery - The Eastern Progress Online
IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets - The Eastern Progress Online
Icecure Medical (XTAE:ICCM) 9-Day RSI : N/A (As of Dec. 05, 2024) - GuruFocus.com
ICCM (Icecure Medical) EBITDA : $-14.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
IceCure's ProSense® Cryoablation Safe and Effective in Destructi - GuruFocus.com
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results - WV News
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2024 Earnings Call Transcript - MSN
H.C. Wainwright reiterates Buy on IceCure Medical stock, FDA decision on ProSense expected soon - Investing.com
HC Wainwright Reiterates Buy Rating for IceCure Medical (NASDAQ:ICCM) - Defense World
IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
IceCure Medical’s sales grow 36% in nine months of 2024 - Medical Buyer
IceCure Receives Notice of Allowance from U.S. Patent and Tradem - GuruFocus.com
IceCure Medical Sees Strong Growth Amid ProSense® Adoption - TipRanks
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates - MSN
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):